Core Viewpoint - The article discusses the ongoing clinical trials of IBI362 (Mastrutide), a dual receptor agonist for GLP-1 and GCG, aimed at treating overweight and obesity in adolescents, highlighting its potential efficacy and safety in this demographic [2][3]. Group 1: Clinical Trials Overview - A Phase III clinical trial (GLORY-YOUNG) is being conducted to evaluate the efficacy and safety of IBI362 in overweight or obese adolescents aged 12 to 18, with a target enrollment of 180 participants across 25 medical institutions [3]. - IBI362 is administered weekly at a dosage of 2 mg (0.5 ml) for a treatment period of 4 weeks [3]. - The drug has already received approval for two indications in adults: long-term weight management for overweight or obese individuals and blood glucose control for adults with type 2 diabetes [3]. Group 2: Ongoing and Completed Studies - IBI362 has completed or is currently involved in eight Phase III clinical studies, including trials for overweight or obese populations and comparisons with other treatments for type 2 diabetes [4][8]. - Notable completed studies include GLORY-1 and DREAMS-3, which have met their primary endpoints, while other studies are still ongoing [6]. - Additional research is being conducted on various conditions, including metabolic-associated fatty liver disease (MAFLD) and heart failure with preserved ejection fraction (HFpEF) [6]. Group 3: Industry Context - The article emphasizes the growing interest in GLP-1 receptor agonists as a new class of diabetes medications that enhance insulin secretion and suppress appetite, thereby aiding in weight loss and blood sugar control [16]. - The GLP-1 industry is supported by a network of professionals and experts, indicating a collaborative effort to advance research and development in this field [12][13].
速递｜针对青少年肥胖！信达生物玛仕度肽启动第8项Ⅲ期临床